The Role of platelets aggregation tests in the diagnosis of clopidogril

resistance rate in patients undergoing pecutaneous coronary

intervension

Introduction:
Platelets play a key role in the pathophysiology of thrombosis after plaque
rupture

(1)

.Plaque rupture occurs spontaneously in patients with acute coronary

syndromes (ACS), or may be

iatrogenically induced in patients undergoing

percutaneous coronary interventions (PCI).significant reduction in such vascular

events in high risk patients with coronary artery diseases or strokes has been
achieved using antiplatelet therapy (2) .
Clopidogrel is a potent antiplatelet drug that is effective in reducing the risk
of vascular events in patients with established vascular disease

(3-5)

.In addition, it

potentiates the effect of aspirin in reducing ischemic and vascular events in the
setting of cardiovascular diseases (6-8). However, a substantial percentage of patients
with Cardiovascular Disease (CAD) showed low or no response to clopidogrel
therapy (9-11) .
The term Clopidogrel Resistance has been used to denote nonresponsiveness of Adenosine Di-Phophatase ADP induced platelet aggregation
following standard clopidogrel therapy(12). Several factors were suggested to
explain low response to clopidogrel; including genetic polymorphisms, cellular
factors e.g. accelerated platelet turnover and drug-drug interaction (13) .

Platelet Aggregation:
1

Adenosine diphosphate plays an important role in platelet activation and

aggregation

(14,15)

. Upon damaged or disrupted endothelium, circulating platelets

adhere to the vessel wall through interactions with the subendothelium constituents
(collagen, von Willebrand factor, and other adhesive proteins such as fibronectin,
laminin, and vitronectin)

(15,16)

. After adhesion, these anchored platelets undergo

conformational changes through the action of several extrinsic activators such as

collagen, thrombin, and epinephrine.Once activated, platelets release the contents
of their dense (platelet agonists such as ADP and serotonin) and alpha-granules
(fibrinogen, von Willebrand factor, other adhesive proteins, proinflammatory
factors, and prothrombotic factors), which trigger platelet-activating intracellular
signals in surrounding platelets. Activated platelets also synthesize and release
thromboxane A2 in circulation. Activated and degranulated platelets expose
glycoprotein (GP) IIb/IIIa receptors at their surface allowing fibrinogen binding,
which forms bridges between adjacent activated platelets causing platelet
aggregation. In addition, the release of granule contents amplifies the coagulation
and inflammatory processes.
ADP and its receptor. Adenosine diphosphate binds to neighboring platelets
through two G-protein coupled receptors (P2Y1 and P2Y12) and the cation
channel-coupled P2X1 receptor (17) (Fig. 1).
The activation of P2X1 receptor mediates a rapid transient calcium ion
influx in platelets but does not play a major role in platelet aggregation (17).
Stimulation of the Gq-coupled P2Y1 receptor activates phospholipase C and
induces a transient rise in cytosolic calcium resulting in a platelet conformational
change and in weak, transient platelet aggregation (18).

Activation of the Gi-coupled P2Y12 receptor by ADP liberates the Gi

protein subunits Gi and , which couple to independent signaling events and
lead to a sustained platelet aggregation (19).
The subunit Gi decreases the platelet cyclic adenosine monophosphate
(cAMP) level through the inhibition of adenylyl cyclase. This decrease in cAMP
production leads, in turn, to a reduction in the activation of specific protein
kinases,which

can

no

longer

phosphorylate

the

vasodilator

stimulated

phosphoprotein (VASP); VASP phosphorylation is crucial for GP IIb/IIIa receptor

inhibition (19).
The subunit activates the phosphatidylinositol 3-kinase, which is an
important signaling molecule for P2Y12-mediated platelet-dense granule secretion
and GP IIb/IIIa receptor activation

(20)

. Signaling events downstream of the P2Y12

receptor mediate thromboxane A2 production, -granule release, and subsequent

expression of P-selectin on activated platelets
involved in thrombus growth and stability

(20)

(21)

. The P2Y12 receptor is also

. Stimulation of both P2Y1 and

P2Y12 receptors is required to cause ADP-induced platelet aggregation (17).

Figure 1: Mechanism of action of clopidogrel.

cAMP= Cyclic adenosine

monophosphate
VASP=Vasodilator stimulated
phosphoprotien
Dotted arrows indicate inhibition
Solid arrows represent activation

CYP450= Cytochrome P450

PGE1 =Prostaglandin E1
PKA =Protien Kinase activation
PLC= Phospholipase C
PI3K= Phosphatidylinositol 3-Kinase
Ac= adenylyl cyclase

Platelets in the pathogenesis of atherothrombosis:

The complicated pathophysiological procedure underlying acute thrombotic
episodes includes interactions between platelets, plaque components and
coagulation factors (22,23) Figure 2.
The rupture of the intima of acoronary artery, following a plaque rupture or a
iatrogenic injury during PCI, exposes the sub-endothelial elements, such as von
Willebrand factor and collagen,to the bloodstream. Specific receptors on the
4

surface of the platelets (GPIa/IIa, GPIb/V/IX, GPVI, etc.) bind the former
molecules, causing the platelet to adhere to the site of the endothelial injury (23,24).
Platelet adhesion leads to activation of the cell through intracellular
metabolic cascades. As a result,platelets aggregate through fibrinogen bridges,
which bind to the activated platelet receptor-integrin IIb3 (GPIIb/IIIa). Activated
platelets release biologically active substances, stored inside the cell or newly
synthesised,among them adenosine diphosphate (ADP), arachidonic acid, plateletactivating factor (PAF) and serotonin, which induce and preserve platelet
activation and aggregation through positive feedback mechanisms(24,25).
The secretion of pre-coagulant factors from the platelets (e.g. Factor V) and
the interaction with the negatively charged phospholipids of the platelet membrane
maximise the reaction of thrombin synthesis,which has been initiated by the
intravascular exposure of tissue factor and is one of the most powerful platelet
activators. These mechanisms may partly explain the recurrence of thrombotic
episodes in patients already on antiplatelet medication, and justify the need for this
type of drug in cases of acute ischaemic events(26,27) .
Apart from the established importance of platelet actions in the thrombotic
procedure, they play a significant role in the formation of the atheromatous plaque.
According to recent reports, they adhere to the endothelium under mild
inflammatory conditions and attract monocytes, which penetrate the subendothelium and are transformed into macrophages and foam cells.
Several adhesion molecules (P-selectin, ICAM-1) and chemokines (MCP-1,
SDF-1, IL1, IL- 8, CD40L, RANTES, ENA-78, etc.) participate in these
intercellular interactions and enhance the inflammation in the arterial wall(28).
5

Apart from monocytes,endothelial progenitor cells (EPCs) are also recruited

by the activated platelets and have the potential to transform into either foam cells,
promoting atherogenesis, or into endothelial cells, leading to endothelial
regeneration (29).

Figure2: Central role of ADP-P2Y12 Receptor Interaction In Platelet Activation And

Aggregation.

Mechanism of action and metabolism of Clopidogrel:

Clopidogrel is a prodrug that requires hepatic conversion into an active
metabolite to exert its antiplatelet response .Most of absorbed clopidogrel (85% to
90%)

is

hydrolyzed

by

carboxylase

to

an

inactive

carboxylic

acid

metabolite,SR26334, whereas the remaining 10% to 15% is rapidly metabolized by

hepatic cytochrome (CYP) P450 isoenzymes in a 2-step process ( Fig. 3).

In the first step, the thiophene ring of clopidogrel is oxidized to 2-oxoclopidogrel, which is then hydrolyzed to a highly labile active metabolite, R130964, which has both carboxylic acid and thiol groups (30-32).
Recent studies indicate that CYP2C19, CYP1A2, and CYP2B6 participate in
the first metabolic step, whereas CYP2C19, CYP2C9, CYP2B6, and CYP3A are
responsible for the second step (30,31) (Fig. 3).
The highly unstable active metabolite, R-130964, covalently binds to
platelet P2Y12 receptor specifically and irreversibly during passage through the
hepatic circulation resulting in inhibition of ADP-induced platelet activationaggregation for the life span of the platelet (33) (Fig 1).
This metabolic activation scheme is consistent with the time-dependent
cumulative inhibition of ADP-induced platelet aggregation as observed with
repeated daily dosing of clopidogrel and is further highlighted by slow recovery of
platelet function following drug withdrawal (34-36).
Multiple lines of evidence strongly suggest that variable and insufficient
active metabolite generation are the primary explanations for clopidogrel response
variability and nonresponsiveness, respectively (37).
Variable levels of active metabolite generation following clopidogrel
administration could be explained by:
1. Variable or limited intestinal absorption, which may be affected by an ABCB1
gene polymorphism (38-40).
2. Functional variability in P450 isoenzyme activity influenced by drug-drug
interactions as well as other factors.
3. Single nucleotide polymorphisms of specific genes encoding CYP450
isoenzymes (41,42).

Figure 3:Clopidogrel response variability is a pharmacokinetic problem primarily influenced by

the activity of cytochrome P450 isoenzymes in the generation of the active metabolite.Absorption
may be affected by polymorphism of the ABCB1 gene.The activity of hepatic cytochrome
isoenzymes are influenced by drug-drug interactions, single nucleotide polymorphisms, and
environmental influences (smoking).

Pharmacokinetic and Pharmacodynamic properties of Clopidegrel:

Clopidogrel is a member of the thienopyridine family, along with ticlopidyne
and prasugrel, and is a powerful antiplatelet agent

(43)

. It is a product, which is

absorbed in the gut with the aid of the ABCB1/MDR1 protein transporter.
Subsequently, it is converted to the active metabolite by several isoforms of
cytochrome P450 in the liver, mainly CYP2C19. CYP3A4, CYP3A5,CYP1A2,
CYP2B6 and CYP2C9 also participate in the procedure.
The maximum concentration of the active metabolite in blood is reached
within 1 hour after administration of 600 mg clopidogrel
8

(44)

. interestingly, 85% of

the absorbed drug is hydrolysed by plasma and intestinal mucosa esterases to form
inactive product. The half-life of the active metabolite after a single or multiple
doses is about 8 hours

(45)

. This active metabolite is a potent selective inhibitor of

the P2Y12ADP receptor, which exerts its action by forming disulphuric bonds with
2 serine residues (ser-17, ser-270) of the receptor molecule.
The maximum inhibitory activity of clopidogrel is reached in 24 hours after
administration of 75 mg, in six hours after 300 mg, and in two hours after 600 mg.
as the P2Y12 receptor blockade is irreversible, and 10% of platelets are renewed
daily, at 5 days after treatment cessation 50% of the circulating platelets will be
completely functional and capable of producing adequate hemostasis(46).

Clopidogrel resistance definition

No single receptor signaling pathway mediating platelet activation is
responsible for all thrombotic complications. Therefore, a single treatment strategy
directed against a specific receptor cannot overcome all thrombotic complications.
With this in mind, it is our opinion that the optimal definition of resistance or non
responsiveness to an antiplatelet agent is the failure of the antiplatelet agent to
inhibit the target of its action. The identification of resistance would therefore
utilize a laboratory technique that detects residual activity of the target. Therefore,
clopidogrel resistance is best demonstrated by evidence of residual post-treatment
9

P2Y12 activity by measuring ADP-induced platelet aggregation before and after

treatment. Since thrombosis involves multiple signaling pathways, treatment
failure is not synonymous with drug resistance (47).

Aim of the study:

To estimate the incidence of clopidogrel resistance among Kurdish
population and to find the predictors of its resistance.

Materials and methods:

This is a prospective study, 100 patients planned to undergo
elective therapeutic percutaneous coronary intervention (PCI) admitted
in the coronary care unit (CCU) will be included in this study. All patient
will receive a loading dose of 300mg of clopidogrel "Plavix" 12 hours
before the PCI and after that will receive a maintenance dose of 75mg of
clopidogrel. The patients are already on maintaining dose of 100mg of
aspirin. Inform consent will be taken from indicated patients.
The first blood sample will be withdrawn for analysis of platelet
function before clopidogrel intake and the second sample will be
withdrawn 24 hours after PCI (i.e the patient received 300mg loading
dose and 75mg maintaining dose of clopidogrel) (48,49).
Platelet aggregation will be tested using the Multiplate analyzer
(Verum Diagnostica GmbH, Munich, Germany) in the hematology
department in the central laboratory.
10

The following instruments will be required:

1. Hirudin containing test tubes.
2. Prewarmed dilute tubes.
3. Agonists reagent (adenosine diphosphate (ADP), arachidonic acid
(ASPI), thrombin receptor activating peptide (TRAP).
4. Multiplate test cell
5. Multiplate analyzer
Estimated cost: 12,500,000 ID

Procedure:
Whole blood impedance aggregometry will be carried out using the novel
multiplate analyzer (Dynabyte medical, Munich, Germany)

(50,51)

. The instrument

analyzes platelet function in whole blood at 37 C by the attachment of platelets

onto metal electrodes, leading to a change of the electrical conductivity (or
impedance), which is continuously recorded. The Multiplate instrument is an
improvement of impedance aggregometry using a computer-controlled 5-channel
device and disposable test cells with a dual sensor unit allowing duplicate analyses
11

with each test. Aggregation is recorded for 6 min. Results are expressed in arbitrary
units. Parameters are the aggregation (maximal aggregation), velocity (steepness of
the curve), and the area under curve (AUC). The application of different activators
facilitates to study, e.g., the effect of several platelet active drugs.
In the present study, thrombin inhibitor(TI)-blood samples (3 ml withdrawn
in a hirudin anticoagulant containing test tube) will be used for the Multiplate
analyses which should be carried out within 30-180 min after blood sampling in
each study participant. The TI-blood diluted with NaCl 0.9% in a 1:1 ratio, and
platelet aggregation determined thereafter in response to stimulation with thrombin
receptor activator peptide 6 with a final concentration of 32 M (TRAP test),
adenosine- 5-diphosphate (ADP) with a final concentration of 6.4 M (ADP
test),and arachidonic acid (ASPI test).Obtained results will be expressed as areas
under the curve (AUC).

The ADP test is used to detect copidogrel response, the ASPI test is for
detection of function of aspirin.
Multiplate- sensitivity to antiplatelet drugs:

Tests

ADP

Sensitivity
Clopidegrel

Aspirin

Positive +

Negative
12

ASPI

Negative

Positive ++

TRAP

Positive/negative

Negative

Laboratory data of complete blood count CBC , fasting blood sugar ,blood
urea ,serum creatinine ,lipid profile (s.cholestrol,s.triglyceride , s.HDL
,s.VLDL,s.LDL) Viral screen (HBs Ag,HCV Ab ,HIV Ab) ,body mass index
(height and weight) ,and clinical history will be taken from patients medical file
according to questionnaire designed for this purpose.

Questionnaire:
Date . //.20

procedure:

..
Mobile number: .
Name:

..

Age: years

..

Months

Sex:
13

Residence:

City Center:

District: / Town: .. /Sub district: .... /

Village:
Ethnicity:

Kurdish

Arabic Turkish ..

others.
Waist circumference ..cm Ht..cm Wt..kg
Lab tests
CBC:
Hb:. gm/dl WBC .

Platelet count

Lipid profile :
s.cholestrol mg/dl
s.triglyceridemg/dl

s.HDL.mg/dl

s.VLDLmg/dl

s.LDL..mg/dl
B.sugar

.mg/dl

Bl.urea

S.creatinine..mg/dl
Viral screen :
14

..mg/dl

HBs ..
HCV..
HIV
Clinical history:
Diabetes mellitus ..

hypertention .

cigarette/day

Smoking.

duration years.

Drug history :
Lipid lower agent.
Proton pump inhibitor
NSAID

Reference list:

1. Fuster V, Stein B, Ambrose JA, Badimon L,Badimon

JJ,ChesebroJH.

Atherosclerotic

plaque

rupture

and

thrombosis. Evolving concepts. Circulation 1990; 82(Suppl

3):II4759.
2. Baigent C, Sudlow C, Collins R, Peto R.. Collaborative
meta-analysis of randomised trials of antiplatelet therapy for
prevention of death, myocardial infarction, and stroke in
15

high risk patients BMJ. 2002 January 12; 324(7329): 7186.

3. Bhatt DL, Marso SP, Hirsch AT, Ringleb PA, Hacke W,
Topol EJ. Amplified benefit of clopidogrel versus aspirin in
patients

with

diabetes

mellitus.

Am

Cardiol.

2002;

90(6):625-628.
4. Gent M. A randomised, blinded, trial of clopidogrel versus
aspirin

in

patients

at

risk

of

ischaemic

events

(CAPRIE).Lancet. 1996;348(9038):1329-1339.
5. Mehta SR, Yusuf S, Peters RJ Bertrand ME, Lewis
BS, Natarajan MK et al.

Effects of pretreatment with

clopidogrel and aspirin followed by long-term therapy in

patients undergoing percutaneous coronary intervention:
the PCI-CURE study. Lancet. 2001;358(9281):527-533.
6. Chen ZM, Jiang LX, Chen YP, Xie JX,Pan HC, Peto
R,Collins R et al. Addition of clopidogrel to aspirin in
45,852

patients

randomised

with

acute

placebo-controlled

myocardial

infarction:

trial.

Lancet.

2005;366(9497):1607-1621.
7. Steinhubl SR, Berger PB, Mann JT, 3rd, Fry ET, DeLago
A, Wilmer C, Topol EJ. Early and sustained dual oral
antiplatelet
intervention:

therapy
a

following

randomized

percutaneous
controlled

coronary

trial.

JAMA.

2002;288(19):2411-2420.
8. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G,
Fox KK. Effects of clopidogrel in addition to aspirin in

16

patients with acute coronary syndromes without ST-segment

elevation. N Engl J Med. 2001;345(7):494-502.
9. Aleil B, Ravanat C, Cazenave JP, Rochoux G, Heitz A,
Gachet C. Flow cytometric analysis of intraplatelet VASP
phosphorylation for the detection of clopidogrel resistance in
patients with ischemic cardiovascular diseases. J Thromb
Haemost. 2005; 3(1):85-92.
10.
Gurbel PA, Bliden KP, Hiatt BL, O'Connor CM.
Clopidogrel for coronary stenting: response variability, drug
resistance, and the effect of pretreatment platelet reactivity.
Circulation. 2003;107(23):2908-2913.
11.
Van der Heijden DJ, Westendorp IC, Riezebos RK,
Kiemeneij F, Slagboom T, der Weiken LR,et al. Lack of
efficacy of clopidogrel pre-treatment in the prevention of
myocardial damage after elective stent implantation. J Am
Coll Cardiol. 2004;44(1): 20-24
12.
Cattaneo M. Aspirin and clopidogrel: efficacy, safety,
and the issue of drug resistance. Arterioscler Thromb Vasc
Biol. 2004;24(11):1980-1987.
13.
Angiolillo DJ, Fernandez-Ortiz

A,

Bernardo

E,Alfonso F, Macaya C, Bass T, et al. Variability in

individual

responsiveness

to

clopidogrel:

clinical

implications, management, and future perspectives. J Am

Coll Cardiol. 2007;49(14):1505-1516.
14.
Woulfe D, Yang J, Brass L. ADP and platelets: the end
of the beginning. J Clin Invest 2001; 107:1503 5.
15.
Stein B, Fuster V, Israel DH, Cohen M, Badimon L,
Badimon

JJ, et

al.

Platelet
17

inhibitor

agents

in

cardiovascular disease: an update. J Am Coll Cardiol 1989;

14:81336.
16.
Schafer AI. Antiplatelet therapy. Am J Med 1996;
101:199 209.
17.
Kunapuli SP, Dorsam RT, Kim S, Quinton TM.
Platelet

purinergic

receptors.

Curr

Opin

Pharmacol

2003;3:175 80.
18.
Jin J, Daniel JL, Kunapuli SP. Molecular basis for ADPinduced platelet activation. II.The P2Y1 receptor mediates
ADP-induced intracellular calcium mobilization and shape
change in platelets. J Biol Chem 1998; 273:20304.
19.
Geiger J, Brich J, Honig-Liedl P,
Eigenthaler
M, Schanzenbcher P,
Herbert J M, Walter U,et al. Specific impairment of human
platelet
P2Y(AC) ADP receptor-mediated signaling by the antiplatelet
drug
clopidogrel. Arterioscler Thromb Vasc Biol 1999; 19:200711.
20.

Conley PB, Delaney SM. Scientific and therapeutic

insights into the role of the platelet P2Y12 receptor in

thrombosis. Curr Opin Hematol 2003; 10:3338.
21.
Dorsam RT, Kunapuli SP. Central role of the P2Y12
receptor in platelet activation. J Clin Invest 2004; 113:340
5.
22.

Ruggeri ZM. Platelets in atherothrombosis. Nature

Med. 2002; 8: 1227-1234.

23.
Dav G, Patrono

C.

Platelet

activation

atherothrombosis. N Engl J Med. 2007; 357: 2482-2494.

18

and

24.

Jennings LK. Mechanisms of platelet activation: need

for new strategies to protect against platelet-mediated

atherothrombosis.Thromb Haemost. 2009; 102: 248-257.
25.
Offermanns S. Activation of platelet function through
G protein-coupled receptors. Circ Res. 2006; 99: 1293-1304.
26.
Mann KG. Thrombin formation. Chest. 2003; 124: 4S10S.
27.
Brummel KE, Paradis SG, Butenas S, Mann KG.
Thrombin

functions

during

tissue

factor-induced

blood

coagulation. Blood. 2002; 100: 148-152.

28.
Lindemann S, Kramer B, Daub K, Stellos K, Gawaz
M. Molecular pathways used by platelets to initiate and
accelerate atherogenesis. Curr Opin Lipidol. 2007; 18: 566573.
29.
Stellos

K,

Gawaz

M.

Platelet

interaction

with

progenitor cells: potential implications for regenerative

medicine. Thromb Haemost. 2007; 98: 922-929.
30.
Hagihara K, Kazui M, Kurihara A, Yoshiike M
Honda K, Okazaki O,

Farid N, et al. A possible

mechanism for the differences in efficiency and variability of

active metabolite formation from thienopyridine antiplatelet
agents, prasugrel and clopidogrel. Drug Metab Dispos 2009;
37:214552.
31.
Kazui M, Nishiya Y, Ishizuka T, Hagihara K, Farid
N, Okazaki

O,

et

al.

Identification

of

the

human

cytochrome P450 enzymes involved in the two oxidative

steps

in

the

bioactivation
19

of

clopidogrel

to

its

pharmacologically active metabolite. Drug Metab Dispos

2010; 38:929.
32.
Pereillo JM,
JM, Maftouh

Maftouh

M, Andrieu

M,

Andrieu

A,

et

al.

A,

Pereillo

Structure

and

stereochemistry of the active metabolite of clopidogrel.

Drug Metab Dispos 2002; 30:1288 95.
33.

Savi

P,

Zachayus

JL,

Delesque-Touchard

N,

Labouret C, Herv C, Uzabiaga MF, et al. The active

metabolite of clopidegrel disrupts P2Y12 receptor oligomers
and partitions them out of lipid rafts. Proc Natl Acad Sci U S
A2006;103:11069 74.
34.
Patrono C, Baigent C, Hirsh J, Roth G, on behalf of
American College of Chest Physicians. Antiplatelet drugs:
American

College

of

Chest

Physicians

evidence-based

clinical practice guidelines (8thedition). Chest 2008; 133

Suppl 6:199S233S.
35.
Price MJ, Coleman JL, Steinhubl SR, Wong GB,
Cannon CP, Teirstein PS. Onset and offset of platelet
inhibition after high-dose clopidogrel loading and standard
daily therapy measured by a pointof- care assay in healthy
volunteers. Am J Cardiol 2006; 98:681 4.
36.
Gurbel PA, Bliden KP, Butler K, Udaya S. Tantry,
Tania Gesheff, Cheryl Wei, et al. Randomized doubleblind assessment of the ONSET and OFFSET of the
antiplatelet

effects

of

ticagrelor

20

versus

clopidogrel

in

patients

with

stable

coronary

artery

disease:

the

ONSET/OFFSET study. Circulation 2009; 120:257785.

37.
Angiolillo DJ, Fernandez-Ortiz A, Bernardo E,
Ramrez

C, Sabat

M, Bauelos

C,

et

al.

High

clopidegrel loading dose during coronary stenting: effects on

drug response and interindividual variability. Eur Heart J
2004; 25:190310.
38.
Simon T, Verstuyft C, Mary-Karuse M, Quteineh
L, Drouet E, Mneveau N, et al., on behalf of French
Registry

of

Myocardial

Acute

ST

Infarction

Elevation
(FAST-MI)

and

Non-ST-Elevation

Investigators.

Genetic

determinants of response to clopidogrel and cardiovascular

events. N Engl J Med 2009; 360:363-75.
39.

Hochholzer

W,

Trenk

D,

Frundi

D,

BlankeP; Fischer B; Andris K ,et al. Time dependence of

platelet inhibition after a 600 mg loading dose of clopidogrel
in a large, unselected cohort of candidates for percutaneous
Coronary intervention. Circulation 2005; 111:25604.
40.
Collet JP, Silvain J, Landivier A, Tanguy M, ; Cayla
G, Bellemain A, et al. Dose effect of clopidegrel reloading
in patients already on 75-mg maintenance dose: the Reload
with Clopidogrel Before Coronary Angioplasty in Subjects
Treated Long Term with Dual Antiplatelet Therapy (RELOAD)
study. Circulation 2008; 118:122533.
41.
Gurbel PA, Antonino MJ, Tantry

US.

Recent

developments in clopidogrel pharmacology and their relation

21

to clinical outcomes. Expert Opin Drug Metab Toxicol 2009;

5:989 1004.
42.
Marn F, Gonzalez-Conejero R, Capranzano P,
Bass TA, Roldan V, Angiolillo DJ. Pharmacogenetics in
cardiovascular antithrombotic

therapy. J Am Coll Cardiol

2009; 54:104157.
43.
Gurbel PA, Tantry US. Combination antithrombotic
therapies. Circulation. 2010; 121:569-583.
44.
Montalescot G, sideris G, meulman C, Bal-ditSollier C, Lellouche N, Steg PG,

et al. a randomized

comparsion of high clopidogrel loading doses in patients

with non-ST-segment elevation acute coronary syndromes:
the ALBION (Assessment of the best loading doses of
clopidogrel) to blunt platelet activation, inflammation and
ongoing necrosis ) trial. J Am Coll Cardiol. 2006; 48:931-938.
45.

Lins R, Broekhuysem J, necciari J,deroubaix X.

pharmakokynatic profile of 14C-labeled clopidogrel. Semin

Thromb Hemost. 1999; 25 suppl 2:29-33.
46.
Tselepis A D,Gerotziafas G,Andrikopoulos G,
Anninos H, Vardas P.Mechanism of platelet activation and
modification of response to antiplatelet agents.Hellenic J
Cardiol.2011;52:128-140.
47.
Gurbel P A, Tantry U S. clopidogrel resistance.
Thrombosis Research. 2007;120:311-321.
48.
Wang L,Wang X,Chen F.clopidogrel resistance is
associated with long-term thrombotic events in patient
implanted

with

drug-eluting

RD.2010;10(4):219-24.
22

stents.Drugs

49.

Thomas

C,Meinhard

M,Benjamin
H.Utility

of

D,Werner
whole

blood

P,Andreas
impedance

aggregometry for the assesment of clopidogrel action using

the

noval

multiplate

analyzer

flowcytometric

comparison

with

two

methods.Thrombosis

Research.2007;121(2):249-258.
50.
Calatzis A, Wittwer M, Krueger B. A new approach
to platelet function analysis in whole bloodthe Multiplate
analyzer. Platelets 2004; 15:479 [Abstract].
51.
Calatzis A, Wittwer M, Krueger B, Spannagl M.
Assessment of cyclooxygenase, ADP receptor and GpIIb/IIIa
receptor blockade by impedance aggregometry using the
Multiplate analyzer. J Thromb Haemost 2005; 3(Suppl
1):0962.

23